Word: ayerst
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
Boosting IGF-1 levels is only half the story. Sweeney is also trying to tip the balance by shutting down myostatin, a compound that inhibits IGF-1 activity in the muscle. The pharmaceutical maker Wyeth Ayerst is testing a myostatin blocker in early trials of healthy humans, and hopes that it may become a new treatment option for those with muscular dystrophy or for the elderly who have become frail from the normal muscle wasting that occurs with aging...
Legal claims proliferated against American Home Products, whose Wyeth-Ayerst subsidiary made Pondimin (or fenfluramine, the "fen" in fen/phen) and marketed the related diet drug Redux. Though many of these suits were combined in a single multibillion-dollar class action, Mundy focuses on Linnen's case and one other. In the latter, a couple of outsize Texas lawyers named Kip Petroff and Robert Kisselburgh brought ole-boy tactics to bear on behalf of Debbie Lovett, 36, a manicurist with valve disease. Their client had a long history of smoking and high blood pressure, which suggests that more than diet drugs...
...most famous of these are Wyeth-Ayerst's Enbrel, and Remicade, made by a subsidiary of Johnson & Johnson, which have been in use for roughly two years. Both inhibit a messenger in the inflammatory cascade known as the tumor necrosis factor (TNF). The drugs are more effective than traditional medications, and more likely to retard joint degradation. "The idea that biologics could prove effective against autoimmune disease has been firmly established by the TNF story," says Dr. H. Michael Belmont of the Hospital for Joint Diseases in New York City...
...first and most famous of these are Wyeth-Ayerst’s Enbrel, and Remicade, manufactured by a subsidiary of Johnson and Johnson, which have been in use now for roughly two years. Both Enbrel and Remicade inhibit a key messenger in the inflammatory cascade known as the tumor necrosis factor (TNF). The drugs are both more effective than traditional medications, and more likely to slow down joint degradation. "The idea that biologics could prove effective against autoimmune diseases has been firmly established by the TNF story," says Dr. H. Michael Belmont of the Hospital for Joint Diseases in New York...
...doesn?t look good for the drug's makers. The lawyers for Debbie Lovett, 36, sounded like they?d watched a tobacco trial or two in their time. They claimed that Wyeth-Ayerst Laboratories, a subsidiary of American Home Products, knew the dangers of fen-phen?s dangerous half, fenfluramine, long before the FDA yanked it off the market in May 1997 -- and hid their research from an unsuspecting public. Which left the defense spluttering that Ms. Lovett?s obesity carried its own risks; she knew what she was getting into. The jury didn...